

PPIA, HRPT1, and PGK1 genes as the appropriate combination for RT-qPCR normalization in alveolar and femoral bone remodeling in olanzapine-treated rats

SARANDA DISHA-IBRAHIMI^{1,2}
GORAZD DREVENŠEK^{3,4}
MARTINA DREVENŠEK^{1,5}
JANJA MARC⁶
IRENA PRODAN ŽITNIK⁶

¹ Department of Orthodontics, Faculty of Medicine
University of Ljubljana, Ljubljana, Slovenia

² Department of Periodontology and Oral Medicine
Faculty of Medicine, University of Prishtina, Prishtina
Kosovo

³ Institute of Pharmacology and Experimental
Toxicology, Faculty of Medicine, University of
Ljubljana, Ljubljana, Slovenia

⁴ Department of Psychology, Faculty of Mathematics
Natural Sciences and Information Technologies
University of Primorska, Koper, Slovenia

⁵ Department of Orthodontics, University Medical
Centre Ljubljana, Ljubljana, Slovenia

⁶ Department of Clinical Biochemistry, Faculty of
Pharmacy, University of Ljubljana, Ljubljana, Slovenia

ABSTRACT

Reliable gene expression analysis in bone remodeling studies requires an appropriate selection of internal controls, *i.e.* stable reference genes for the normalization of quantitative real-time PCR (RT-qPCR), the most common method used for quantifying gene expression measurements. Even the most widely used reference genes can have variable expression under different experimental conditions, or in different tissue types or treatment regimes, so selecting appropriate controls is a key step in ensuring reliable results. The aim of this research was to identify the most stable reference gene(s) for the study of olanzapine modulated bone remodeling in rats. RNA was isolated from the maxillary alveolar and femoral bones of olanzapine or placebo-treated Wistar rats and transcribed to cDNA. The expression of 12 candidate reference genes was assessed by RT-qPCR. Their expressions were analysed using GeNorm, NormFinder, BestKeeper and delta Ct algorithms, and by the comprehensive ranking method. *PPIA*, *HRPT1* and *PGK1* were the most stably expressed reference genes and the combination of the three genes was optimal for normalization. This study is the first to identify the optimal reference genes for research in olanzapine-exposed rats, which serve as a pivotal benchmark for enhancing the accuracy and reliability of future RT-qPCR expression in bone studies.

Keywords: reference genes, alveolar bone, RT-qPCR, rat, olanzapine

Accepted August 8, 2024
Published online August 9, 2024

INTRODUCTION

In bone biology research, analyzing gene expression patterns is a common technique for understanding the mechanisms and signaling pathways involved in bone formation and remodeling (1–4). Quantitative reverse transcription polymerase chain reaction (RT-qPCR) stands as the predominant method for this, particularly when evaluating a limited

* Correspondence; e-mail: martina.drevensek@kclj.si

number of genes (5). This tool offers high sensitivity, reproducibility, and repeatability (1). However, the outcomes of RT-qPCR can be influenced by various factors such as the starting quantity of mRNA, its purity and integrity, the reverse transcription yield, and the amplification efficiency (6, 7). Consequently, the incorporation of internal control becomes imperative. For normalization, several strategies can be used, with the most frequent being normalization against an endogenous reference gene exhibiting stable expression across all specific tissue samples (8, 9).

The choice of an appropriate reference gene for normalization in gene expression studies is crucial to ensure accurate and reliable results. Ideally, a reference gene should exhibit consistent expression levels in the specific tissues and cells, while being minimally influenced by the experimental conditions. While many studies conventionally employ a single reference gene for normalization, certain widely used reference genes in rat tissue expression analyses, such as beta-actin (*ACTB*), glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), 18S rRNA (*RRN18S*), hypoxanthine-guanine phosphoribosyltransferase (*HPRT1*), and beta-2-microglobulin (*B2M*), have demonstrated inconsistent and unstable expression patterns across different experimental conditions (5, 8). It is therefore strongly recommended that the selection of reference genes be carried out on an individual basis for each research group, considering the specific tissues, treatment regimens, and experimental conditions (8, 10–12).

Several conventionally utilized reference genes may not be optimal for normalizing gene expression concerning bone markers during bone cell differentiation (12–14). Limited data exists on the selection of reference genes specific to rat alveolar bone tissue. According to Kirschneck *et al.*, the most stable combinations of reference genes for combined dental, periodontal, and alveolar bone in rats include peptidylprolyl isomerase B (*PPIB*) and tyrosine 3/tryptophan 5-monooxygenase activation protein, zeta polypeptide (*YWHAZ*) genes in untreated rats, and *PPIB* and *B2M* in orthodontically forced rats (15). For developing rat long bones, succinate dehydrogenase (*SDHA*) and TATAA-box binding protein (*TBP*) emerged as the most stable during the prenatal phase, while postnatally the highest stability was observed with *YWHAZ* and *GAPDH* (16).

Many investigations have probed gene expression influenced by olanzapine across various tissues and species; however, the majority lack details on their reference gene selection methodology (17–19). Predominantly, studies focusing on olanzapine-induced gene expression in rats were conducted on brain tissue and often employed a single reference gene without prior validation of its suitability. The genes *ACTB* and *GAPDH* were frequently chosen in these studies (20–23).

To date, no research has meticulously assessed the stability of reference gene expression in olanzapine-treated rat bone tissues, and no universally accepted reference gene or gene combination has been identified. While olanzapine is known to influence bone tissue (24), its precise mechanism remains elusive. Some studies have associated olanzapine with induced bone resorption and bone loss (25–27), while others have reported its role in increasing bone density (28, 29). Given the potential multifaceted impact of olanzapine on bone, multiple signaling pathways may be involved. The influence of olanzapine on the Wnt/ β -catenin signaling pathway, acknowledged as pivotal in bone turnover, emerges as a potential candidate for investigation (30).

The primary objective of this study focused on examining the expression stability of 12 candidate reference genes. This is geared towards identifying robust internal control

genes for analyzing olanzapine-induced bone remodeling in rat alveolar and femoral bones. To achieve this, we employed the comparative delta Ct method, geNorm, NormFinder, and BestKeeper algorithms, and a comprehensive ranking system to assess the stability of these candidate genes.

EXPERIMENTAL

Animal model and bone collection

We undertook an experiment involving 12 male Wistar rats, aged between 16 and 18 weeks at the start of the study. Animal treatment and care adhered to previously established methodologies (31, 32). All the rats were maintained under standardized housing conditions with a regulated temperature (23–25 °C) and humidity, and a consistent 12-hour circadian cycle. Their diet consisted of the Teklad Global Rodent Diet 2016 (Harlan Laboratories, The Netherlands), complemented by unrestricted access to water.

Six of these rats were administered a daily dose of 2 mg kg⁻¹ olanzapine (Krka d.d, Slovenia) *p.o.* over an 8-week period. The remaining rats, serving as controls, were given a placebo (saline solution) for the same time duration. After the 8-week period, all the animals were euthanized. The maxilla of each rat was cut in half, retaining the left segment inclusive of all teeth. All the soft tissue components, such as mucosa, musculature, and ligatures, were removed, ensuring only the osseous and dental tissues remained. From the femur, the distal third was sectioned, capturing the epiphysis, metaphysis, and a fragment of the diaphysis – a region renowned for heightened bone turnover under physiological parameters. Similarly, the non-osseous tissues, inclusive of musculature, ligatures, ligaments, and bone marrow within the medullary cavity, were removed from the femur. Subsequently, all the specimens were promptly preserved in liquid nitrogen.

Precautions were taken to prevent RNA degradation, which was critical to maintaining the integrity of the samples. Sterilized instruments were utilized throughout the sample collection phase. Additionally, RNaseZap spray (Ambion, USA) was applied to all surfaces and tools in direct contact with the tissue samples. The excision of the soft tissues from the samples was conducted on chilled glass plates to further preserve the sample quality.

All the procedures involving animals and the overarching study protocol were subject to review, and received approval from the “Ethics Committee for Animal Experiments of the Administration of the Republic of Slovenia for Food Safety, the Veterinary Sector, and Plant Protection” (Approval No. 34401-62/2008/20). All the methodologies and care protocols strictly adhered to the guiding principles outlined in “The Care and Use of Animals”.

RNA extraction and cDNA synthesis

The frozen samples underwent mechanical pulverization in liquid nitrogen using a mortar and pestle. The extraction of RNA adhered to previously published methodologies (33). Once optimal granularity was achieved, an aliquot of each powdered specimen weighing 120 ± 30 mg was collected in a 1.5-mL microcentrifuge tube infused with 1 mL of Trizol (TRIzol Plus RNA Purification System, Life Technologies, USA) to inhibit RNA degradation. This mixture was subsequently subjected to ultrasonic homogenization to diminish sample viscosity, thereby augmenting cellular membrane lysis and facilitating

enhanced RNA release from the cells. RNA extraction ensued, utilizing the PureLink RNA Mini Kit (Invitrogen, USA) in alignment with the prescribed manufacturer's protocols. The RNA concentration and purity metrics were determined spectrophotometrically by a NanoDrop ND-1000 (Thermo Fischer Scientific, USA). Meanwhile, the structural integrity of the RNA was assessed utilizing the Agilent RNA 6000 Nano Kit (Agilent Technologies, USA) alongside the Bioanalyzer 2100 (Agilent Technologies). The RNA extracted from the bone samples of all 12 animals demonstrated RNA integrity number (RIN) values above 7 and was deemed suitable for subsequent complementary DNA (cDNA) synthesis.

For cDNA synthesis, reverse transcription was carried out in a PeqSTAR Thermal Cycler (Peqlab Biotechnologie, Germany) using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA), adhering to the manufacturer's guidelines. Each transcription reaction incorporated 750 ng of RNA. The reaction parameters were as follows: an initial phase at 25 °C for 10 minutes, 37 °C for 120 minutes, and 85 °C for 5 minutes. Post-transcription, cDNA samples were preserved at –20 °C pending subsequent analyses.

Quantitative RT-PCR assay

A quantitative RT-PCR assay was used to evaluate the stability of the candidate reference genes across distinct sample cohorts, specifically the maxillary and femur bone tissues extracted from the rats given either a placebo or olanzapine. The assay utilized the TATAA Reference Gene Panel (A103P, TATAA Biocenter AB, Sweden) in conjunction with the HOT FIREPol Probe qPCR Mix Plus (Solis BioDyne, Estonia). This panel encompasses assays for 12 reference genes: *ACTB*, *B2M*, *GAPDH*, beta-glucuronidase (*GUSB*), *HPRT1*, phosphoglycerate kinase 1 (*PGK1*), peptidylprolyl isomerase A (cyclophilin A, *PPIA*), 60S acidic ribosomal protein P0 (*RPLP*), *RRN18S*, *TBP*, tubulin beta 5 class I (*TUBB5*), and *YWHAZ*.

All the reactions were carried out on the LightCycler 480 platform (Roche Diagnostics Ltd., Switzerland). Each reaction, with a total volume of 20 µL, adhered to the manufacturer's directives. The amplification parameters were defined as follows: an initial denaturation at 95 °C for 12 minutes, succeeded by 40 amplification cycles comprising 15 seconds at 95 °C and 45 seconds at 60 °C, and concluding with a final elongation phase at 40 °C for 30 minutes. Both standards and sample assays were made in duplicate to ensure consistency.

To maintain the integrity and accuracy of the assay, several controls were used. A positive control evaluated the polymerase chain reaction efficiency; a no-template control (NTC) confirmed the absence of reagent contamination; and a no reverse transcriptase control (NRT) assessed gDNA contamination in the RNA samples.

Analysis of reference gene stability

For data analysis, we used GeNorm and NormFinder algorithms, the comparative delta Ct method, and BestKeeper software.

GeNorm: This algorithm determines gene stability based on the M value, which measures the average pairwise variation of a reference gene against all other reference genes. Genes with an M value below 1.5 are considered stable, with those having the lowest M values exhibiting the most stable expression. Additionally, GeNorm determines the optimal number of reference genes required for normalization by calculating the pairwise variation values (V) between normalization factors after stepwise inclusion of the reference genes,

based on their M-values. The inclusion of each additional reference gene can result in a decrease or increase in the V-value. A cut-off for the V-value was set at 0.15, below which the inclusion of additional reference genes is not required for normalization (6).

NormFinder: This algorithm utilizes a mathematical model to evaluate both intra- and intergroup variability in reference gene expression. Combining these factors produces a candidate gene stability value. The model further suggests the optimal number and the best combination of the reference genes (34).

Comparative Delta Ct Method: This method compares the relative expression of gene pairs within each sample to identify the most stably expressed reference genes. For all gene pairs and across all samples, delta Ct values were calculated by subtracting the Ct value of one candidate gene from the Ct value of another within the same sample. The standard deviation (SD) of the delta Ct values was determined for each pair of genes and the mean SD for each candidate gene was calculated, based on its pairwise comparisons with the other candidate genes. Genes with lower mean SDs are considered more stable because their expression levels are less variable relative to genes with higher mean SDs (35).

BestKeeper Software: BestKeeper analyses the expression levels of up to ten candidate genes to identify the optimal reference genes through pairwise correlation analysis. Initially, genes are ranked based on the variation in their threshold cycle (Ct). Greater variation, represented by the standard deviation (SD) of the Ct values, points to lower expression stability. Genes with an SD exceeding 1 are viewed as unstable and are excluded. The software then computes the BestKeeper index for each sample as the geometric mean of all the stable candidate gene Ct values. The correlation between this index and individual genes is ascertained using Pearson correlation analysis. Notably, the most stable genes are characterized by a low SD value and a high correlation coefficient. Since BestKeeper can only analyze ten candidate genes and our panel had twelve, we excluded the two least stable genes (YWHAZ and TUBB5) based on the NormFinder results (36).

Finally, to evaluate the collective stability of the reference genes, we derived a comprehensive ranking using the geometric means of the ranks obtained from the described algorithms.

RESULTS AND DISCUSSION

Our study aimed to identify the most suitable reference genes for examining bone remodeling modulated by olanzapine. We evaluated the gene expression stability of our chosen candidate genes across four distinct sample groups: maxillary and femur bone tissues from rats, treated with olanzapine or given a placebo. Initial evaluation using descriptive statistics revealed that all the candidate genes hit the detection threshold with similar Ct values. This suggests consistent expression levels in both olanzapine-treated and untreated bones, be they alveolar or femoral. Of the genes, *RRN18S* displayed the highest expression levels, having median Ct values ranging from 7.64 to 8.01. In contrast, *TBP* was the least expressed, with Ct values between 27.55 and 28.75. Fig. 1 illustrates the distribution of Ct values for each gene across the sample groups. As expected, no amplification was observed in the NTC, confirming the absence of reagent contamination or primer dimer formation. In the NRT, low-level amplification was observed only for the most highly expressed gene, *RRN18S*, suggesting minor gDNA contamination. The Ct

values were much higher in the NRT versus the mean Ct of the other samples (35.4 and 7.8, respectively), which indicates that less than 0.0000008 % of the total signal originates from gDNA, which was considered negligible. No amplification product was present in the NRT for the other candidate genes. For positive control, the amplification product was present in all the reactions at Ct values below 30.

To ascertain the most consistently expressed reference genes, we analyzed our results with the geNorm, NormFinder, and BestKeeper algorithms, in addition to the delta Ct and comprehensive ranking methods.

GeNorm analysis

GeNorm is a widely used tool for reference gene selection. It calculates the average pairwise variation between a candidate gene and all others, ranking them by their stability value, or M value. Genes with the lowest M values are considered to have the most stable expression. A recommended cut-off M value of 1.5 is used to identify stable genes. To determine the ideal number of reference genes for qRT-PCR normalization, pairwise variation values were calculated with the cut-off set at 0.15. If below this threshold, adding another reference gene is unlikely to enhance data normalization (6). In our study, the M values for all the evaluated candidate genes were under 1.5, ranging between 0.151 and




Fig. 1. Median and distribution of Ct values for each candidate gene obtained with RT-qPCR in: a) maxilla in placebo-treated rats; b) femur in placebo-treated rats; c) maxilla in olanzapine-treated rats and d) femur in olanzapine-treated rats. Each box shows the lower 25th and upper 75th percentiles with median Ct values; the whiskers mark the minimum and maximum of the Ct values in each data set.

0.506. ACTB and TBP emerged as the most stable genes, both having an M value of 0.151. The pairwise variation analysis indicated that the best number of reference genes for RT-qPCR normalization was four, with the prime combination being ACTB, TBP, HRPT1, and PPIA (Table I and Fig. 2).

Table I. Expression stability of candidate reference genes. Ranking by GeNorm, NormFinder, and BestKeeper algorithms, delta Ct analysis, and comprehensive ranking using the geometric mean

Rank	GeNorm		NormFinder		BestKeeper		Delta Ct		Comprehensive ranking	
	Gene name	M-value	Gene	Stability value	Gene	SD	Gene	Average of SD	Gene	Geometric mean
1	ACTB TBP	0.151	PPIA	0.065	PPIA	0.24	HRPT1	0.37	PPIA	1.6
2	–	–	HRPT1	0.077	PGK1	0.25	PPIA	0.37	HRPT1	2.3
3	HRPT1	0.188	PGK1	0.097	HRPT1	0.28	PGK1	0.4	PGK1	3.2
4	PPIA	0.198	ACTB	0.221	GAPDH	0.31	TBP	0.4	TBP	3.5
5	PGK1	0.211	RRN18S	0.225	GUSB	0.39	ACTB	0.42	ACTB	3.9
6	GAPDH	0.234	TBP	0.235	TBP	0.39	GAPDH	0.43	GAPDH	5.6
7	GUSB	0.260	GAPDH	0.265	B2M	0.44	RRN18S	0.46	RRN18S	6.5
8	RRN18S	0.289	GUSB	0.360	ACTB	0.45	GUSB	0.48	GUSB	6.9
9	B2M	0.314	B2M	0.369	–	–	B2M	0.52	B2M	8.5
10	TUBB5	0.340	RPLP	0.433	–	–	TUBB5	0.57	TUBB5	10.3
11	RPLP	0.384	TUBB5	0.503	–	–	RPLP	0.59	RPLP	10.7
12	YWAHZ	0.506	YWAHZ	1.095	–	–	YWAHZ	1.14	YWAHZ	12.0




Fig. 2. Expression stability of candidate reference genes, calculated with GeNorm: a) ranking based on average stability numbers (M values); b) pairwise variation analysis for the determination of the minimal number of required reference genes for reliable normalization.

NormFinder analysis

Unlike GeNorm, which ranks genes by pairwise variation, NormFinder uses a mathematical model-based approach to estimate both intra- and intergroup variability in reference gene expression. This is then combined into a candidate gene's stability value (SV). The gene with the lowest SV is deemed the most stable. Additionally, NormFinder can determine the optimal number of reference genes for reliable normalization by computing the cumulative standard deviation as each gene is added (34). According to this algorithm, the optimal number of reference genes for investigating olanzapine-influenced bone remodeling is three. The prime trio consists of *PPIA*, *HRPT1*, and *PGK1*, with a combined SV of 0.047. Notably, these genes also exhibit the lowest individual stability values, at 0.065, 0.077, and 0.097, respectively (Table I and Fig. 3).

Comparative delta Ct analysis

The ΔCt method examines the relative expression between pairs of candidate genes within each sample, determining gene expression stability by evaluating the consistency of expression differences across the samples. In our study, the Ct values ranged from 7.8 for *RRN18S* to 27.8 for *TBP*. As shown in Fig. 4, *PPIA* and *HRPT1* emerged as the most stable genes, with average standard deviation values of 0.37. Conversely, *YWAHZ* and *RPLP* were the least stable, exhibiting average SDs of 1.14 and 0.59, respectively (Table I).

BestKeeper analysis

BestKeeper initially ranks candidate reference genes based on the standard deviation (SD) of their Ct values. In our study, the SD values of all 10 included genes were below 1, deeming every candidate gene stable. The most stable gene was *RRN18S* (SD = 0.08), followed in order by *PPIA* (SD = 0.24), *PGK1* (SD = 0.25), *RPLP* (SD = 0.26), and *HRPT1* (SD = 0.28). A deeper ranking involved calculating the pairwise correlation of candidate genes and their correlation with the BestKeeper index (Table I). *RRN18S* and *RPLP* were marked




Fig. 3. Expression stability of candidate reference genes calculated with NormFinder: a) ranking based on calculated stability value (SV); b) determination of optimal number of reference genes using accumulated standard deviation calculation for each added candidate gene.




Fig. 4. a) Ct values of all candidate reference genes. Each box shows the lower 25th and upper 75th percentiles with median Ct values; the whiskers mark the minimum and maximum of the Ct values in each data set; b) expression stability determined using the comparative delta Ct method.

as unstable due to their weak correlation with the BestKeeper index, having correlation coefficients of 0.354 and -0.049 , and p -values of 0.250 and 0.876, respectively (Table II). Consequently, these genes were omitted from further analysis.

Comprehensive ranking

The GeNorm, NormFinder, and BestKeeper algorithms utilize unique methodologies to assess gene expression stability. While there was a general consistency in the rankings from each method, we observed some discrepancies in our results. Given the comparable reliability of all the methods, we aimed for a consensus by introducing a comprehensive ranking system. This system calculated the geometric mean of the individual rankings created by each algorithm.

Table II. Repeated pairwise correlation analysis of candidate reference genes vs. BestKeeper index (BK)

	Coefficient of correlation	p -value
<i>GAPDH</i> vs. BK	0.830	0.001
<i>GUSB</i> vs. BK	0.710	0.010
<i>HRPT1</i> vs. BK	0.932	0.001
<i>PGK1</i> vs. BK	0.876	0.001
<i>PPIA</i> vs. BK	0.944	0.001
<i>ACTB</i> vs. BK	0.965	0.001
<i>RPLP</i> vs. BK	-0.049	0.876
<i>RRN18S</i> vs. BK	0.359	0.250
<i>TBP</i> vs. BK	0.909	0.001
<i>B2M</i> vs. BK	0.793	0.002

From this consolidated analysis, three genes demonstrated notably consistent stability: *PPIA*, *HRPT1*, and *PGK1*, with a geometric mean (GM) rankings of 1.6, 2.3, and 3.2, respectively. Conversely, the genes *YWAHZ*, *RPLP*, *TUBB5*, and *B2M* were identified as the least stable, having GM rankings of 12.0, 10.7, 10.3, and 8.7 respectively, as detailed in Table I.

We assessed the expression stability of twelve candidate reference genes related to bone remodeling in rat alveolar (calvarial) bone and femur, under the influence of the antipsychotic drug olanzapine. These genes were selected based on their prevalent use in bone research. Their stability was determined and ranked using five distinct methods: GeNorm, NormFinder, the delta Ct method, BestKeeper, and a comprehensive ranking method.

Choosing appropriate reference genes specific to the experimental conditions is crucial for ensuring the reliability of results in expression studies using qPCR (37). In rat bone expression research, *GAPDH* and *ACTB* are frequently used as reference genes, often without prior validation. However, numerous studies highlight that these genes' expression can vary significantly based on the experimental protocols, tissue choice, and treatment, so the assumption that traditionally employed reference genes remain stable under all conditions is misguided. It is essential to select fitting internal controls tailored to the distinct conditions of each study (13, 37–45).

Kirschneck *et al.* (15) determined the most stable genes for dental, periodontal, and alveolar bone tissue in rats under different experimental conditions. They evaluated genes in control rats, those with periodontitis, and those with an applied orthodontic coil placed between the molars and incisors. Their findings suggested *PPIB*, *YWAHZ*, and *ACTB* to be the most stable under their overall conditions. Consequently, they recommended using *PPIB* and *YWAHZ* as reference genes in rat dental research.

In our study, we evaluated the stability of the candidate reference genes in alveolar and femoral rat bone, comparing groups treated with olanzapine to those given a placebo. The four algorithms used for ranking gene stability provided similar outcomes, with three genes, *PPIA*, *HRPT1*, and *PGK1*, consistently among the top five in stability. The other two varied: *ACTB* and *TBP* were highlighted by the GeNorm and delta Ct methods; *ACTB* and *RRN18S* by NormFinder; and *GAPDH* and *GUSB* by BestKeeper. A comprehensive ranking determined *PPIA*, *HRPT1*, *TBP*, *PGK1*, and *ACTB* to be the most stable candidates. Although BestKeeper initially ranked *RRN18S* as the most stable and included *RPLP* in its top five, their weak correlation with the BestKeeper index led to their exclusion from the final ranking. It is noteworthy that while most studies continue to use a single reference gene for normalization, this approach can cause bias and inaccuracies in up to 25 % of cases (6).

Our findings strongly recommend the use of multiple reference genes, especially when examining subtle differences in gene expression. According to GeNorm and NormFinder, the ideal number of reference genes for our experimental conditions stands at four and three, respectively. GeNorm recommends *ACTB*, *TBP*, *HRPT1*, and *PPIA*, whereas NormFinder suggests *PPIA*, *HRPT1*, and *PGK1*. Notably, GeNorm identified *TBP* and *ACTB* as the most stable candidates, but these genes received considerably lower rankings from the other algorithms. This discrepancy could be attributed to GeNorm's inherent bias towards co-regulated genes. Based on our findings, we recommend utilizing a combination of *PPIA*, *HRPT1*, and *PGK1* for studies on olanzapine-induced bone remodeling. Conversely, we caution against relying on *B2M*, *TUBB5*, *RPLP*, and *YWAHZ*, due to their consistently low stability rankings in our tests.

Our findings concur with several other studies, suggesting that *ACTB*, and especially *GAPDH*, have better-suited alternatives as reference genes for studying bone remodeling in olanzapine-treated rats. While our selection varies greatly from previously published results, it is crucial to note that most of those studies did not focus on bone tissue. Interestingly, none of the genes demonstrating high stability in our study ranked highly in our earlier models (46, 47). This underscores the importance of meticulously selecting reference genes before any target gene expression analysis. Tailoring this choice based on the study's design and objectives can greatly enhance the quality of the results.

CONCLUSIONS

In this study, we emphasized the importance of tailored reference gene selection when examining bone remodeling modulated by olanzapine in rats. By employing methodologies such as GeNorm, NormFinder, BestKeeper, comparative delta Ct, and comprehensive ranking, we determined that traditionally used reference genes such as *ACTB* and *GAPDH* may not be appropriate for this specific research model. Our findings suggest the utilization of a trio of reference genes, *PPIA*, *HRPT1*, and *PGK1*, for more accurate normalization of RT-qPCR results in our model. This research accentuates the need for an optimal selection of reference genes, which should be harmonized with the study's protocol, tissue selection, and objectives to derive reliable and unbiased results.

Availability of data – The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflict of interest – The authors declare no conflict of interest.

Funding – This work was supported by the P3-0293 research programme financed by the Slovenian Research Agency and Ad Futura – the Slovenian Human Resources Development and Scholarship Fund. The funders had no role in the design and conduct of the study, the analysis and interpretation of the data, or the preparation, approval, and submission of the manuscript for publication.

Authors contributions – Conceptualization, G.D, M.D. and J.M.; investigation, I.P.Ž. and S.D.I.; original draft preparation, G.D. and I.P.Ž.; review and editing, G.D., M.D., J.M. and I.P.Ž. All the authors have read and agreed with the published version of the manuscript.

REFERENCES

1. K. Okamura, Y. Inagaki, T. K. Matsui, M. Matsubayashi, T. Komeda, M. Ogawa, E. Mori and Y. Tanaka, RT-qPCR analyses on the osteogenic differentiation from human iPS cells: an investigation of reference genes, *Sci. Rep.* 10(1) (2020) 1–10; <https://doi.org/10.1038/s41598-020-68752-2>
2. X. Tu, J. Delgado-Calle, K. W. Condon, M. Maycas, H. Zhang, N. Carlesso, M. M. Taketo, D. B. Burr, L. I. Plotkin and T. Bellido, Osteocytes mediate the anabolic actions of canonical Wnt/ β -catenin signaling in bone, *Proc. Natl. Acad. Sci. U S A*, 112(5) (2015) E478–86; <https://doi.org/10.1073/pnas.1409857112>
3. M. R. Rad, D. Liu, H. He, H. Brooks, M. Xiao, G. E. Wise and S. H. Yao, The role of dentin matrix protein 1 (DMP1) in regulation of osteogenic differentiation of rat dental follicle stem cells (DFSCs), *Arch. Oral Biol.* 60(4) (2015) 546–556; <https://doi.org/10.1016/j.archoralbio.2014.12.013>
4. C. Zhang, H. Dai and B. de Crombrughe, Characterization of Dkk1 gene regulation by the osteoblast-specific transcription factor *Osx*, *Biochem. Biophys. Res. Commun.* 420(4) (2012) 782–786; <https://doi.org/10.1016/j.bbrc.2012.03.073>

5. T. Svingen, H. Letting, N. Hadrup, U. Hass and A. M. Vinggaard, Selection of reference genes for quantitative RT-PCR (RT-qPCR) analysis of rat tissues under physiological and toxicological conditions, *PeerJ*. **3** (2015) 1–15; <https://doi.org/10.7717/peerj.855>
6. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe and F. Speleman, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, *Genome Biol.* **3**(7) (2002) 1–12; <https://doi.org/10.1186/gb-2002-3-7-research0034>
7. S. A. Bustin, V. Benes, J. A. Garson, J. Hellems, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M. W. Pfaffl, G. L. Shipley, J. Vandesompele and C. T. Wittwer, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, *Clin. Chem.* **55**(4) (2009) 611–622; <https://doi.org/10.1373/clinchem.2008.112797>
8. J. Huggett, K. Dheda, S. Bustin and A. Zumla, Real-time RT-PCR normalisation; strategies and considerations, *Genes Immun.* **6**(4) (2005) 279–284; <https://doi.org/10.1038/sj.gene.6364190>
9. K. Goossens, M. Van Poucke, A. Van Soom, J. Vandesompele, A. Van Zeveren, and L. J. Peelman, Selection of reference genes for quantitative real-time PCR in bovine preimplantation embryos, *BMC Dev. Biol.* **5**(27) (2005) 1–9; <https://doi.org/10.1186/1471-213X-5-27>
10. B. Kozera and M. Rapacz, Reference genes in real-time PCR, *J. Appl. Genet.* **54**(4) (2013) 391–406; <https://doi.org/10.1007/s13353-013-0173-x>
11. A. Al-Sabah, P. Stadnik, S. J. Gilbert, V. C. Duance and E. J. Blain, Importance of reference gene selection for articular cartilage mechanobiology studies, *Osteoarthritis Cartilage* **24**(4) (2016) 719–730; <https://doi.org/10.1016/j.joca.2015.11.007>
12. T. He, Y. Huang, J. C. Chak and R. M. Klar, Recommendations for improving accuracy of gene expression data in bone and cartilage tissue engineering, *Sci. Rep.* **8**(1) (2018) 1–13; <https://doi.org/10.1038/s41598-018-33242-z>
13. E. Ragni, M. Viganò, P. Rebullà, R. Giordano and L. Lazzari, What is beyond a qRT-PCR study on mesenchymal stem cell differentiation properties: how to choose the most reliable housekeeping genes, *J. Cell Mol. Med.* **17**(1) (2013) 168–180; <https://doi.org/10.1111/j.1582-4934.2012.01660.x>
14. X. Yang, J. T. Hatfield, S. J. Hinze, X. Mu, P. J. Anderson and B. C. Powell, Bone to pick: the importance of evaluating reference genes for RT-qPCR quantification of gene expression in craniosynostosis and bone-related tissues and cells, *BMC Res. Notes* **5**(222) (2012) 1–9; <https://doi.org/10.1186/1756-0500-5-222>
15. C. Kirschneck, P. Proff, J. Fanghänel, M. Wolf, J. C. Roldán and P. Römer, Reference genes for valid gene expression studies on rat dental, periodontal and alveolar bone tissue by means of RT-qPCR with a focus on orthodontic tooth movement and periodontitis, *Ann. Anat.* **204** (2016) 93–105; <https://doi.org/10.1016/j.aanat.2015.11.005>
16. H. Han, L. Liu, M. Chen, Y. Liu, H. Wang and L. Chen, The optimal compound reference genes for qRT-PCR analysis in the developing rat long bones under physiological conditions and prenatal dexamethasone exposure model, *Reprod. Toxicol.* **98** (2020) 242–251; <https://doi.org/10.1016/j.reprotox.2020.10.008>
17. R. Li, J. Ou, L. Li, Y. Yang, J. Zhao and R. Wu, The Wnt signaling pathway effector TCF7L2 mediates olanzapine-induced weight gain and insulin resistance, *Front Pharmacol.* **9**(379) (2018) 1–13; <https://doi.org/10.3389/fphar.2018.00379>
18. Ł. Mokros, M. S. Karbownik, K. Nowakowska-Domagala, J. Szemraj, Ł. Wieteska, K. Woźniak, A. Witusik, A. Antczak and T. Pietras, Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line, *Biol. Rhythm Res.* **47**(6) (2016) 865–871; <https://doi.org/10.1080/09291016.2016.1202379>
19. Y. Yang, M. Shen, L. Li, Y. Long, L. Wang, B. Lang and R. Wu, Olanzapine promotes the occurrence of metabolic disorders in conditional TCF7L2-knockout mice, *Front Cell Dev. Biol.* **10** (2022) 1–13; <https://doi.org/10.3389/fcell.2022.890472>

20. H. Li, S. Peng, S. Li, S. Liu, Y. Lv, N. Yang, L. Yu, Y. Deng, Z. Zhang, M. Fang, Y. Huo, Y. Chen, T. Sun and W. Li, Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance, *Sci. Rep.* **9** (2019) 1–12; <https://doi.org/10.1038/s41598-018-36930-y>
21. A. Pałasz, P. Żarczyński, K. Bogus, K. Mordecka-Chamera, A. Della Vecchia, J. Skałbania, J. J. Worthington, M. Krzystanek and M. Żarczyńska, Modulatory effect of olanzapine on SMIM20/phoenixin, NPQ/spexin and NUCB2/nesfatin-1 gene expressions in the rat brainstem, *Pharmacol. Reports* **73**(4) (2021) 1188–1194; <https://doi.org/10.1007/s43440-021-00267-7>
22. S. S. Evers, G. J. Boersma, K. L. Tamashiro, A. J. Scheurink and G. van Dijk, Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression, *J. Psychopharmacol.* **31**(11) (2017) 1437–1452; <https://doi.org/10.1177/0269881117724749>
23. M. He, Q. Zhang, C. Deng, T. Jin, X. Song, H. Wang and X. Huang, Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity, *Psychoneuroendocrinology* **85** (2017) 190–199; <https://doi.org/10.1016/j.psyneuen.2017.08.022>
24. A. Uçok and W. Gaebel, Side effects of atypical antipsychotics: a brief overview, *World Psychiatry* **7**(1) (2008) 58–62; <https://doi.org/10.1002/j.2051-5545.2008.tb00154.x>
25. V. O’Keane and A. M. Meaney, Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? *J. Clin. Psychopharmacol.* **25**(1) (2005) 26–31; <https://doi.org/10.1097/01.jcp.0000150223.31007.e0>
26. Y. Roke, P. N. van Harten, J. K. Buitelaar, D. E. Tenback, L. G. B. A. Quekel, Y. B. de Rijke and A. M. Boot, Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment, *Eur. J. Endocrinol.* **167**(6) (2012) 855–863; <https://doi.org/10.1530/EJE-12-0521>
27. B. Zhang, L. Deng, H. Wu, X. Lu, L. Peng, R. Wu, W. Guo, J. Chen, L. Li and J. Zhao, Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β -CrossLaps, *Schizophr. Res.* **176**(2–3) (2016) 259–263; <https://doi.org/10.1016/j.schres.2016.06.034>
28. D. Becker, O. Liver, R. Mester, M. Rapoport, A. Weizman and M. Weiss, Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients, *J. Clin. Psychiatry* **64**(7) (2003) 761–766; <https://doi.org/10.4088/jcp.v64n0704>
29. A. M. Meaney and V. O’Keane, Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables, *Schizophr. Res.* **93**(1–3) (2007) 136–143; <https://doi.org/10.1016/j.schres.2007.01.013>
30. Y. Chen and B. A. Alman, Wnt pathway, an essential role in bone regeneration, *J. Cell Biochem.* **106**(3) (2009) 353–362; <https://doi.org/10.1002/jcb.22020>
31. M. Drevensek, S. Sprogar, I. Boras and G. Drevensek, Effects of endothelin antagonist tezosentan on orthodontic tooth movement in rats, *Am. J. Orthod. Dentofacial Orthop.* **129**(4) (2006) 555–558; <https://doi.org/10.1016/j.ajodo.2005.12.016>
32. S. Sprogar, T. Vaupotic, A. Cör, M. Drevensek and G. Drevensek, The endothelin system mediates bone modeling in the late stage of orthodontic tooth movement in rats, *Bone* **43**(4) (2008) 740–747; <https://doi.org/10.1016/j.bone.2008.06.012>
33. A. Plut, S. Sprogar, G. Drevensek, S. Hudoklin, J. Zupan, J. Marc and M. Drevensek, Bone remodeling during orthodontic tooth movement in rats with type 2 diabetes, *Am. J. Orthod. Dentofacial Orthop.* **148**(6) (2015) 1017–1025; <https://doi.org/10.1016/j.ajodo.2015.05.031>
34. C. L. Andersen, J. L. Jensen and T. F. Ørntoft, Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for

- normalization, applied to bladder and colon cancer data sets, *Cancer Res.* **64**(15) (2004) 5245–5250; <https://doi.org/10.1158/0008-5472.CAN-04-0496>
35. N. Silver, S. Best, J. Jiang and S. L. Thein, Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR, *BMC Mol. Biol.* **7**(33) (2006) 1–9; <https://doi.org/https://doi.org/10.1186/1471-2199-7-33>
36. M. W. Pfaffl, A. Tichopad, C. Prgomet and T. P. Neuvians, Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations, *Biotechnol. Lett.* **26**(6) (2004) 509–515; <https://doi.org/10.1023/b:biel.0000019559.84305.47>
37. R. P. F. Abuna, F. S. Oliveira, J. I. R. Ramos, H. B. Lopes, G. P. Freitas, A. T. P. Souza, M. M. Beloti and A. L. Rosa, Selection of reference genes for quantitative real-time polymerase chain reaction studies in rat osteoblasts, *J. Cell Physiol.* **234**(1) (2018) 749–756; <https://doi.org/10.1002/jcp.26886>
38. G. Elberg, D. Elberg, C. J. Logan, L. Chen and M. A. Turman, Limitations of commonly used internal controls for real-time RT-PCR analysis of renal epithelial-mesenchymal cell transition, *Nephron Exp. Nephrol.* **102**(3–4) (2006) 113–122; <https://doi.org/10.1159/000090070>
39. T. Fink, P. Lund, L. Pilgaard, J. G. Rasmussen, M. Duroux and V. Zachar, Instability of standard PCR reference genes in adipose-derived stem cells during propagation, differentiation and hypoxic exposure, *BMC Mol. Biol.* **9**(98) (2008) 1–9; <https://doi.org/10.1186/1471-2199-9-98>
40. S. Selvey, E. W. Thompson, K. Matthaei, R. A. Lea, M. G. Irving and L. R. Griffiths, Beta-actin – an unsuitable internal control for RT-PCR, *Mol. Cell Probes* **15**(5) (2001) 307–311; <https://doi.org/10.1006/mcpr.2001.0376>
41. D. Studer, S. Lischer, W. Jochum, M. Ehrbar, M. Zenobi-Wong and K. Maniura-Weber, Ribosomal protein L13a as a reference gene for human bone marrow-derived mesenchymal stromal cells during expansion, adipo-, chondro-, and osteogenesis, *Tissue Eng. Part C Methods* **18**(10) (2012) 761–771; <https://doi.org/10.1089/ten.TEC.2012.0081>
42. C. Tricarico, P. Pinzani, S. Bianchi, M. Paglierani, V. Distanti, M. Pazzagli, S. A. Bustin and C. Orlando, Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies, *Anal. Biochem.* **309**(2) (2002) 293–300; [https://doi.org/10.1016/s0003-2697\(02\)00311-1](https://doi.org/10.1016/s0003-2697(02)00311-1)
43. F. G. Quiroz, O. M. Posada, D. Gallego-Perez, N. Higueta-Castro, C. Sarassa, D. J. Hansford, P. Agudelo-Florez and L. E López, Housekeeping gene stability influences the quantification of osteogenic markers during stem cell differentiation to the osteogenic lineage, *Cytotechnology* **62**(2) (2010) 109–120; <https://doi.org/10.1007/s10616-010-9265-1>
44. H. Ma, Q. Yang, D. Li and J. Liu, Validation of suitable reference genes for quantitative polymerase chain reaction analysis in rabbit bone marrow mesenchymal stem cell differentiation, *Mol. Med. Rep.* **12**(2) (2015) 2961–2968; <https://doi.org/10.3892/mmr.2015.3776>
45. A. S. Stephens, S. R. Stephens and N. A. Morrison, Internal control genes for quantitative RT-PCR expression analysis in mouse osteoblasts, osteoclasts and macrophages, *BMC Res. Notes* **4**(410) (2011) 1–9; <https://doi.org/10.1186/1756-0500-4-410>
46. M. Lunder, G. Drevenšek, D. Černe, J. Marc, M. Janić and M. Šabovič, Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas, *J. Cardiovasc. Pharmacol. Ther.* **18**(2) (2013) 177–1783; <https://doi.org/10.1177/1074248412463966>
47. M. Janic, M. Lunder, D. Cerne, J. Marc, A. Jerin, M. Skitek, G. Drevensek and M. Sabovic, The "rise-peak-fall" pattern of time dependency of the cardiovascular pleiotropic effects of treatment with low-dose atorvastatin, losartan, and a combination thereof in rats, *J. Cardiovas.c Pharmacol.* **68**(1) (2016) 74–80; <https://doi.org/10.1097/FJC.0000000000000393>